Cargando…
Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria
By sequencing autozygous human populations, we identified a healthy adult woman with lifelong complete knockout of HAO1 (expected ~1 in 30 million outbred people). HAO1 (glycolate oxidase) silencing is the mechanism of lumasiran, an investigational RNA interference therapeutic for primary hyperoxalu...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108859/ https://www.ncbi.nlm.nih.gov/pubmed/32207686 http://dx.doi.org/10.7554/eLife.54363 |
_version_ | 1783512851160236032 |
---|---|
author | McGregor, Tracy L Hunt, Karen A Yee, Elaine Mason, Dan Nioi, Paul Ticau, Simina Pelosi, Marissa Loken, Perry R Finer, Sarah Lawlor, Deborah A Fauman, Eric B Huang, Qin Qin Griffiths, Christopher J MacArthur, Daniel G Trembath, Richard C Oglesbee, Devin Lieske, John C Erbe, David V Wright, John van Heel, David A |
author_facet | McGregor, Tracy L Hunt, Karen A Yee, Elaine Mason, Dan Nioi, Paul Ticau, Simina Pelosi, Marissa Loken, Perry R Finer, Sarah Lawlor, Deborah A Fauman, Eric B Huang, Qin Qin Griffiths, Christopher J MacArthur, Daniel G Trembath, Richard C Oglesbee, Devin Lieske, John C Erbe, David V Wright, John van Heel, David A |
author_sort | McGregor, Tracy L |
collection | PubMed |
description | By sequencing autozygous human populations, we identified a healthy adult woman with lifelong complete knockout of HAO1 (expected ~1 in 30 million outbred people). HAO1 (glycolate oxidase) silencing is the mechanism of lumasiran, an investigational RNA interference therapeutic for primary hyperoxaluria type 1. Her plasma glycolate levels were 12 times, and urinary glycolate 6 times, the upper limit of normal observed in healthy reference individuals (n = 67). Plasma metabolomics and lipidomics (1871 biochemicals) revealed 18 markedly elevated biochemicals (>5 sd outliers versus n = 25 controls) suggesting additional HAO1 effects. Comparison with lumasiran preclinical and clinical trial data suggested she has <2% residual glycolate oxidase activity. Cell line p.Leu333SerfsTer4 expression showed markedly reduced HAO1 protein levels and cellular protein mis-localisation. In this woman, lifelong HAO1 knockout is safe and without clinical phenotype, de-risking a therapeutic approach and informing therapeutic mechanisms. Unlocking evidence from the diversity of human genetic variation can facilitate drug development. |
format | Online Article Text |
id | pubmed-7108859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-71088592020-04-01 Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria McGregor, Tracy L Hunt, Karen A Yee, Elaine Mason, Dan Nioi, Paul Ticau, Simina Pelosi, Marissa Loken, Perry R Finer, Sarah Lawlor, Deborah A Fauman, Eric B Huang, Qin Qin Griffiths, Christopher J MacArthur, Daniel G Trembath, Richard C Oglesbee, Devin Lieske, John C Erbe, David V Wright, John van Heel, David A eLife Genetics and Genomics By sequencing autozygous human populations, we identified a healthy adult woman with lifelong complete knockout of HAO1 (expected ~1 in 30 million outbred people). HAO1 (glycolate oxidase) silencing is the mechanism of lumasiran, an investigational RNA interference therapeutic for primary hyperoxaluria type 1. Her plasma glycolate levels were 12 times, and urinary glycolate 6 times, the upper limit of normal observed in healthy reference individuals (n = 67). Plasma metabolomics and lipidomics (1871 biochemicals) revealed 18 markedly elevated biochemicals (>5 sd outliers versus n = 25 controls) suggesting additional HAO1 effects. Comparison with lumasiran preclinical and clinical trial data suggested she has <2% residual glycolate oxidase activity. Cell line p.Leu333SerfsTer4 expression showed markedly reduced HAO1 protein levels and cellular protein mis-localisation. In this woman, lifelong HAO1 knockout is safe and without clinical phenotype, de-risking a therapeutic approach and informing therapeutic mechanisms. Unlocking evidence from the diversity of human genetic variation can facilitate drug development. eLife Sciences Publications, Ltd 2020-03-24 /pmc/articles/PMC7108859/ /pubmed/32207686 http://dx.doi.org/10.7554/eLife.54363 Text en © 2020, McGregor et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Genetics and Genomics McGregor, Tracy L Hunt, Karen A Yee, Elaine Mason, Dan Nioi, Paul Ticau, Simina Pelosi, Marissa Loken, Perry R Finer, Sarah Lawlor, Deborah A Fauman, Eric B Huang, Qin Qin Griffiths, Christopher J MacArthur, Daniel G Trembath, Richard C Oglesbee, Devin Lieske, John C Erbe, David V Wright, John van Heel, David A Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria |
title | Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria |
title_full | Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria |
title_fullStr | Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria |
title_full_unstemmed | Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria |
title_short | Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria |
title_sort | characterising a healthy adult with a rare hao1 knockout to support a therapeutic strategy for primary hyperoxaluria |
topic | Genetics and Genomics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108859/ https://www.ncbi.nlm.nih.gov/pubmed/32207686 http://dx.doi.org/10.7554/eLife.54363 |
work_keys_str_mv | AT mcgregortracyl characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT huntkarena characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT yeeelaine characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT masondan characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT nioipaul characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT ticausimina characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT pelosimarissa characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT lokenperryr characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT finersarah characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT lawlordeboraha characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT faumanericb characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT huangqinqin characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT griffithschristopherj characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT macarthurdanielg characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT trembathrichardc characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT oglesbeedevin characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT lieskejohnc characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT erbedavidv characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT wrightjohn characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria AT vanheeldavida characterisingahealthyadultwithararehao1knockouttosupportatherapeuticstrategyforprimaryhyperoxaluria |